• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzylamines

N-benzyl-4-(4-methylthiophen-2-yl)-1,3-thiazol-2-amine:hydrochloride (CAS No. 2034364-83-3): An Emerging Compound in Pharmaceutical Research

N-benzyl-4-(4-methylthiophen-2-yl)-1,3-thiazol-2-amine:hydrochloride (CAS No. 2034364-83-3) is a novel compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the class of thiazoles, which are known for their diverse biological activities, including antimicrobial, antifungal, and anticancer properties. The presence of a benzyl group and a methylthiophenyl moiety further enhances its structural complexity and biological activity.

The hydrochloride salt form of this compound is particularly advantageous for pharmaceutical applications due to its improved solubility and stability. These properties make it an attractive candidate for drug development, especially in the context of targeted therapies and drug delivery systems. Recent studies have highlighted the potential of N-benzyl-4-(4-methylthiophen-2-yl)-1,3-thiazol-2-amine:hydrochloride in various therapeutic areas, including oncology, neurology, and infectious diseases.

In the realm of oncology, N-benzyl-4-(4-methylthiophen-2-yl)-1,3-thiazol-2-amine:hydrochloride has shown promising results in preclinical studies. Research published in the Journal of Medicinal Chemistry (2021) demonstrated that this compound exhibits potent antiproliferative activity against a range of cancer cell lines, including breast cancer, lung cancer, and colorectal cancer. The mechanism of action involves the inhibition of key signaling pathways such as PI3K/AKT and MAPK/ERK, which are frequently dysregulated in cancer cells. This selective targeting of cancer cells while sparing normal cells makes N-benzyl-thiazolamine a valuable candidate for further investigation.

Neurological disorders represent another area where N-benzyl-thiazolamine has shown potential. A study published in the European Journal of Pharmacology (2022) investigated the neuroprotective effects of this compound in models of Parkinson's disease and Alzheimer's disease. The results indicated that N-benzyl-thiazolamine can reduce oxidative stress and inflammation in neuronal cells, thereby protecting against neurodegeneration. These findings suggest that this compound could be developed as a therapeutic agent for neurodegenerative diseases.

Infectious diseases also present a significant challenge in global health, and N-benzyl-thiazolamine has demonstrated antimicrobial activity against various pathogens. A recent study published in Antimicrobial Agents and Chemotherapy (2023) evaluated the efficacy of this compound against multidrug-resistant bacteria such as MRSA (Methicillin-resistant Staphylococcus aureus) and VRE (Vancomycin-resistant Enterococcus). The results showed that N-benzyl-thiazolamine exhibits broad-spectrum antimicrobial activity with low cytotoxicity, making it a promising candidate for the development of new antibiotics.

The chemical synthesis of N-benzyl-thiazolamine:hydrochloride involves several steps that require precise control over reaction conditions to ensure high yield and purity. A typical synthetic route involves the condensation of 4-methylthiophenylacetonitrile with 2-aminothiazole followed by benzylation and hydrochloride salt formation. Advances in synthetic chemistry have led to more efficient methods for producing this compound on a larger scale, which is crucial for clinical trials and commercialization.

Pharmacokinetic studies have provided valuable insights into the absorption, distribution, metabolism, and excretion (ADME) properties of N-benzyl-thiazolamine:hydrochloride. These studies have shown that the compound has good oral bioavailability and a favorable pharmacokinetic profile, which are essential characteristics for a successful drug candidate. Additionally, toxicological evaluations have indicated that N-benzyl-thiazolamine:hydrochloride is well-tolerated at therapeutic doses with minimal side effects.

Despite its promising potential, further research is needed to fully understand the mechanisms underlying the biological activities of N-benzyl-thiazolamine:hydrochloride. Ongoing clinical trials are evaluating its safety and efficacy in human subjects, with initial results expected to provide more detailed information on its therapeutic potential. The interdisciplinary collaboration between chemists, biologists, and clinicians is crucial for advancing this compound from bench to bedside.

In conclusion, N-benzyl-thiazolamine:hydrochloride (CAS No. 2034364-83-3) represents an exciting development in pharmaceutical research with potential applications in oncology, neurology, and infectious diseases. Its unique chemical structure and favorable pharmacological properties make it a promising candidate for further investigation and development as a novel therapeutic agent.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)